Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors

Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors

Previous studies have suggested that statins can be repurposed for cancer treatment. However, the therapeutic efficacy of statins in chronic myeloid leukemia (CML) has not yet been demonstrated. In this study, we retrospectively evaluated the outcomes of 408 CML patients who underwent imatinib thera...

Full description

Bibliographic Details
Main Authors: Hyeok-Jae Jang, Young-Min Woo, Kazuhito Naka, Jong-Ho Park, Ho-Jae Han, Hee-Jin Kim, Sun-Hee Kim, Jae-Sook Ahn, Taehyung Kim, Shinya Kimura, Sarah Zarabi, Jeffrey H. Lipton, Mark D. Minden, Chul-Won Jung, Hyeoung-Joon Kim, Jong-Won Kim, Dennis Dong Hwan Kim
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Cancers
Subjects:
CML
drug resistance
statin
tyrosine kinase inhibitor
combination therapy
Online Access:https://www.mdpi.com/2072-6694/13/21/5543

Internet

https://www.mdpi.com/2072-6694/13/21/5543

Similar Items